The good old Madam !
As noted - in my opinion.
Point is - you say the Teva R/ship is dubious...fair enough as well because like me its your opinion.
However I say Teva R/ship is solid and thick (based on CEO comments and analyst notes).
And from my point of view, I also say it would make logical sense that the r/ship could be further enhanced with the following announcements:
19/3/2015:
MESOBLAST SELECTED FOR FAST TRACK ACCESS TO POTENTIAL INVESTMENT INCENTIVES IN JAPAN ; and
27/3/2015:
MESOBLAST KEY PATENT ALLOWED IN JAPAN FOR THE TREATMENT OF HEART DISEASES, STROKE, AND OTHER VASCULAR CONDITIONS
Teva have a good presence in Japan and with the support of JETRO - why wouldn't any commercially driven Pharma look to take advantage of the "new" Regenerative Medicine laws in Japan – particularly when there are potentiall significant incentives.
Madam – do you see any negatives in the above 2 announcements ?
DYOR. Above just in my opinion.
GLTAH - 2015
- Forums
- ASX - By Stock
- MSB
- Trading high volume
Trading high volume, page-151
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.10 |
Change
0.000(0.00%) |
Mkt cap ! $1.250B |
Open | High | Low | Value | Volume |
$1.09 | $1.13 | $1.08 | $5.380M | 4.893M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 69437 | $1.09 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.10 | 19999 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 69437 | 1.085 |
21 | 236832 | 1.080 |
7 | 104317 | 1.075 |
11 | 370859 | 1.070 |
2 | 53400 | 1.065 |
Price($) | Vol. | No. |
---|---|---|
1.095 | 19999 | 1 |
1.100 | 35400 | 3 |
1.105 | 32188 | 2 |
1.110 | 42480 | 5 |
1.120 | 97563 | 8 |
Last trade - 16.10pm 10/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |
The Watchlist
I88
INFINI RESOURCES LIMITED
Charles Armstrong, CEO
Charles Armstrong
CEO
SPONSORED BY The Market Online